Table 5.
Efficacy of Approved Preferred Antiviral Therapies in Adults With Treatment-Naïve CHB and Immune Active Disease (Not Head-to-Head Comparisons)
| Peg-IFN* (%) | Entecavir† (%) | Tenofovir† (%) | |
|---|---|---|---|
| HBeAg-Positive | |||
| HBV DNA suppression‡ | 30–42 (<2,000–40,000 IU/mL) | 61 (<50–60 IU/mL) | 76 (<60 IU/mL) |
| 8–14 (<80 IU/mL) | |||
| HBeAg loss | 32–36 | 22–25 | — |
| HBeAg seroconversion | 29–36 | 21–22 | 21 |
| Normalization ALT|| | 34–52 | 68–81 | 68 |
| HBsAg loss | 2–7 (6 mos post-treatment) | 2–3 (1 yr) | 3 (1 yr) |
| 11 (at 3 yrs post-treatment) | 4–5 (2 yrs) | 8 (3 yrs) | |
| (References) | 31,33–35 | 36–38 | 30,39 |
| HBeAg-Negative | |||
| HBV DNA suppression§ | 43 (<4,000 IU/mL) | 90–91 | 93 |
| 19 (<80 IU/mL) | |||
| Normalization ALT|| | 59 | 78–88 | 76 |
| HBsAg loss (%) | 4 (6 mos post-treatment) | 0–1 (1 yr) | 0 (1 yr) |
| 6 (at 3 yrs post-treatment) | |||
| (References) | 40,41 | 42 | 39 |
*
Assessed 6 months after completion of 12 months of therapy.
†
Assessed after 2–3 years of continuous therapy.
‡
HBV DNA <2,000–40,000 IU/mL for Peg-IFN; <60 IU/mL for entecavir and tenofovir.
§
HBV DNA <20,000 IU/mL for Peg-IFN; <60 IU/mL for entecavir and tenofovir.
||
ALT normalization defined by laboratory normal.